Agios

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology.

CEO

Brian M. Goff

CEOBrian M. Goff

Employees

540

Employees540

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2007

Founded2007

Employees

540

Employees540

AGIO Key Statistics

Market cap

1.86B

Market cap1.86B

Price-Earnings ratio

-4.65

Price-Earnings ratio-4.65

Dividend yield

—

Dividend yield—

Average volume

1.46M

Average volume1.46M

High today

$31.10

High today$31.10

Low today

$28.93

Low today$28.93

Open price

$29.27

Open price$29.27

Volume

501.05K

Volume501.05K

52 Week high

$46.00

52 Week high$46.00

52 Week low

$22.24

52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $31.02, with a market capitalization of 1.86B. The stock trades at a price-to-earnings (P/E) ratio of -4.65.

During the trading session on 2026-11-09, Agios(AGIO) shares reached a daily high of $31.10 and a low of $28.93. At a current price of $31.02, the stock is +7.2% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 501.05K, compared to an average daily volume of 1.46M.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 19h

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty - TipRanks

...

Simply Wall St 1d

Agios Pharmaceuticals, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Agios Pharmaceuticals, Inc. ( ) defied analyst predictions to release its third-quarter results, which were ahead of market expectations. Revenues beat expectat...

Simply Wall St 4d

Is Agios Pharmaceuticals A Bargain Following Record Revenue And An FDA Review Delay?

Agios Pharmaceuticals (AGIO) just packed several developments into one stretch. Record third quarter revenue from mitapivat in thalassemia, a longer FDA review...

Analyst ratings

70%

of 10 ratings

Buy

70%

Hold

30%

Sell

More AGIO News

Zacks 4d

Agios Pharmaceuticals Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO Quick QuoteAGIO - Free Report) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss...

Simply Wall St 6d

What Agios Pharmaceuticals's FDA Review Delay Means For Shareholders

Agios Pharmaceuticals reported that the FDA extended the PDUFA goal date for mitapivat’s sickle cell disease sNDA to February 1, 2027, after classifying updated...

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Palantir Technologies

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.